Stockhead on MSN36m
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
Twas the week before Christmas and the good news was flowing for clinical stage biotech Neurizon Therapeutics (ASX:NUZ), ...
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase ...
Stockhead on MSN1d
Neurizon files key IND application with US FDA for motor neurone disease drug
Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...
Stockhead on MSN2d
Positive interim study results for Neurizon’s motor neuron disease drug
Neurizon Therapeutics has reported a positive interim eight-month update on its ongoing 12-month open-label extension (OLE) ...
PR Newswire29d
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of NUZ ...
Stockhead on MSN1d
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Percheron Therapuetic's key trial for Duchenne muscular dystrophy has flopped, sending the shares into freefall ...
The Courier-Mail3d
Positive interim study results for Neurizon’s motor neuron disease drug
Neurizon has reported positive eight-month interim data from its open-label extension study in patients with ALS (motor neuron disease). Don't miss out on the headlines from Stockhead. Followed ...
The Daily Telegraph3d
Positive interim study results for Neurizon’s motor neuron disease drug
NUZ-001 shows encouraging results in slowing disease progression and increasing life expectancy of patients with ALS Patients are now in their 27th month of continuous treatment with NUZ-001 ...